Download PDF
Thromb Haemost 2018; 118(10): 1690-1700
DOI: 10.1055/s-0038-1670704
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis

Karin P. M. van Galen
1   Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
Merel Timmer
1   Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
Piet de Kleijn
1   Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2   Department of Rehabilitation, Physical Therapy Science and Sports, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
,
Frank W. G. Leebeek
3   Department of Hematology, Erasmus University Medical Center, Erasmus University, Rotterdam, The Netherlands
,
Wouter Foppen
4   Department of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
Roger E. G. Schutgens
1   Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
Jeroen Eikenboom
5   Department of Thrombosis and Hemostasis and Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden University, Leiden, The Netherlands
,
Karina Meijer
6   Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Karin Fijnvandraat
7   Department of Pediatric Hematology, Academisch Medisch Centrum, Emma Children's Hospital, Amsterdam, The Netherlands
,
Britta A. P. Laros-van Gorkom
8   Department of Hematology, Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands
,
Jos W. Twisk
9   Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, VU University, Amsterdam, The Netherlands
,
Eveline P. Mauser-Bunschoten
1   Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
Kathelijn Fischer
10   Department of Epidemiology, Van Creveldkliniek and Julius Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
,
on behalf of the WiN Studygroup › Author Affiliations Funding This research has been funded by unrestricted research grants from CLS Behring and Bayer.
Further Information

Publication History

16 April 2018

08 August 2018

Publication Date:
01 October 2018 (online)

    Permissions and Reprints

Abstract

Long-term outcome after joint bleeds in von Willebrand disease (VWD) (von Willebrand factor activity ≤ 30 IU/dL) could differ from moderate or severe haemophilia A (HA) (factor VIII [FVIII] 1–5 IU/dL or FVIII < 1 IU/dL). We performed a post hoc analysis on Haemophilia Joint Health Score (HJHS, 0–124), X-ray Pettersson scores (PS, 0–13/joint) and the Haemophilia Activities List (HAL, 0–100), using multivariable regression to adjust for age (rate ratio [RR] or odds ratio [OR] [95% confidence interval]). We included 48 VWD (median age, 47 years, type 3 VWD, n = 19), 39 moderate HA (median, 39 years) and 59 severe HA patients (median, 25 years) with documented joint bleeds. VWD patients suffered repeated bleeding (lifetime > 5/joint) less often than moderate and severe HA patients (52% vs. 77% vs. 98%). HJHS and PS in VWD were similar to moderate HA (median HJHS 5 vs. 6, RR 0.9 [0.5–1.4] and PS > 3 of ≥ 1 joint OR 0.3 [0.1–1.4]), but better than in severe HA patients (median HJHS 5 vs. 9, RR 1.8 [1.1–2.9]; PS > 3 in any joint OR 0.1 [0.0–0.3]). Self-reported limitations in activities were comparable across VWD, moderate HA (HAL score < 95: 67% vs. 49%; OR 1.4 [0.5–3.6]) and young adults with severe HA (67% vs. 48%; OR 1.7 [0.7–4.4]). Despite fewer joint bleeds, joint outcome after joint bleeds was similar in VWD and moderate HA patients. Type 3 VWD patients had worst joint outcome, comparable to younger intensively treated severe HA patients. Limitations in activities occurred as often in VWD as in both moderate and severe HA.

Keywords

von Willebrand disease - joint bleed - arthropathy - haemophilia A - HJHS - Pettersson - HAL

Note

The authors presented part of the findings in this manuscript at the Scientific Conference on Bleeding Disorders of the European Hematology Association 2016, September 14–17, in Barcelona, Spain (oral presentation) and at the 58th Annual Congress of the American Society of Hematology 2016, December 1–6, in San Diego, United States.


Authors' Contributions

Karin P.M. van Galen: Performing research, writing the paper and analysed data. Merel Timmer and Piet de Kleijn: Performing research and writing the paper. Frank W.G. Leebeek: Supervising and analysing the data and writing the paper. W. Foppen: Performing research. Roger E.G. Schutgens, Jeroen Eikenboom, Karina Meijer, Karin Fijnvandraat and Britta A.P. Laros-van Gorkom: Made substantial contributions to the data analyses and writing of the paper. Jos W. Twisk: Designing data analysis plan and supervising writing the paper sections on statistical analysis and results. Evelien P. Mauser-Bunschoten and Kathelijn Fischer: Designing the research, supervising data analysis and writing the paper.


Supplementary Material

 

  • References

  • 1 Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
    CrossrefPubMedGoogle Scholar
  • 2 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16 (01) 20-32
    PubMedGoogle Scholar
  • 3 de Wee EM, Sanders YV, Mauser-Bunschoten EP. , et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 van Galen KP, Sanders YV, Vojinovic U. , et al; WiN Study Group. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia 2015; 21 (03) e185-e192
    CrossrefPubMedGoogle Scholar
  • 5 Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FP, van Vulpen LF. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res 2017; 115: 192-199
    CrossrefPubMedGoogle Scholar
  • 6 Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143 (05) 632-640
    PubMedGoogle Scholar
  • 7 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedGoogle Scholar
  • 8 Nichols WL, Hultin MB, James AH. , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 9 van Galen KP, Mauser-Bunschoten EP, Leebeek FW. Hemophilic arthropathy in patients with von Willebrand disease. Blood Rev 2012; 26 (06) 261-266
    CrossrefPubMedGoogle Scholar
  • 10 Ahlberg A, Silwer J. Arthropathy in von Willebrand's disease. Acta Orthop Scand 1970; 41 (05) 539-544
    CrossrefPubMedGoogle Scholar
  • 11 Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1-159
    PubMedGoogle Scholar
  • 12 Sumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States. Haemophilia 2004; 10 (04) 360-366
    CrossrefPubMedGoogle Scholar
  • 13 van Galen KPM, de Kleijn P, Foppen W. , et al; Win study group. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica 2017; 102 (09) 1486-1493
    CrossrefPubMedGoogle Scholar
  • 14 Fischer K, Nijdam A, Holmström M. , et al. Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined. Haemophilia 2016; 22 (02) e80-e86
    CrossrefPubMedGoogle Scholar
  • 15 Fischer K, de Kleijn P. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia 2013; 19 (06) 944-950
    CrossrefPubMedGoogle Scholar
  • 16 Hilliard P, Funk S, Zourikian N. , et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12 (05) 518-525
    CrossrefPubMedGoogle Scholar
  • 17 Fischer K, Steen Carlsson K, Petrini P. , et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122 (07) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 18 van Galen KPM, Timmer MA, de Kleijn P. , et al. Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health Score and Haemophilia Activities List. Thromb Haemost 2017; 117 (08) 1465-1470
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002; 43 (05) 528-532
    CrossrefPubMedGoogle Scholar
  • 20 Hamel J, Pohlmann H, Schramm W. Radiological evaluation of chronic hemophilic arthropathy by the Pettersson score: problems in correlation in adult patients. Skeletal Radiol 1988; 17 (01) 32-36
    CrossrefPubMedGoogle Scholar
  • 21 van Genderen FR, Westers P, Heijnen L. , et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12 (01) 36-46
    CrossrefPubMedGoogle Scholar
  • 22 den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus 2014; 12 (Suppl. 01) s330-s336
    PubMedGoogle Scholar
  • 23 de Wee EM, Leebeek FWG, Eikenboom JCJ. Diagnosis and management of von Willebrand disease in The Netherlands. Semin Thromb Hemost 2011; 37 (05) 480-487
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Fischer K, van der Bom JG, Mauser-Bunschoten EP. , et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7 (05) 446-452
    CrossrefPubMedGoogle Scholar
  • 25 Foppen W, van der Schaaf IC, Beek FJ, Verkooijen HM, Fischer K. Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlas. Eur Radiol 2016; 26 (06) 1963-1970
    CrossrefPubMedGoogle Scholar
  • 26 Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia 1998; 4 (04) 413-417
    CrossrefPubMedGoogle Scholar
  • 27 Jette AM, Keysor JJ. Disability models: implications for arthritis exercise and physical activity interventions. Arthritis Rheum 2003; 49 (01) 114-120
    CrossrefPubMedGoogle Scholar
  • 28 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; (149) 153-159
    PubMedGoogle Scholar
  • 29 Nijdam A, Foppen W, De Kleijn P. , et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost 2016; 115 (05) 931-938
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 van Genderen FR, van Meeteren NL, van der Bom JG. , et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10 (05) 565-571
    CrossrefPubMedGoogle Scholar
  • 31 den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17 (01) 41-44
    CrossrefPubMedGoogle Scholar
  • 32 Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol 2016; 53 (01) 35-39
    CrossrefPubMedGoogle Scholar
  • 33 Sood SL, Cuker A, Wang C. , et al; HTCN Study Investigators. Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia 2013; 19 (04) 595-601
    CrossrefPubMedGoogle Scholar
  • 34 Soucie JM, Wang C, Forsyth A. , et al; Hemophilia Treatment Center Network. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17 (03) 500-507
    CrossrefPubMedGoogle Scholar
  • 35 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; 77: 77 , 3–132
    PubMedGoogle Scholar
  • 36 Roosendaal G, Tekoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatol 2000; 27 (07) 1740-1744
    PubMedGoogle Scholar
  • 37 van Vulpen LFD, Mastbergen SC, Lafeber FPJG, Schutgens REG. Differential effects of bleeds on the development of arthropathy - basic and applied issues. Haemophilia 2017; 23 (04) 521-527
    CrossrefPubMedGoogle Scholar
  • 38 Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995; 38 (08) 1134-1141
    CrossrefPubMedGoogle Scholar
  • 39 Buchbinder D, Ragni MV. What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia?. Hematology (Am Soc Hematol Educ Program) 2013; 2013 (13) 52-55
    CrossrefPubMedGoogle Scholar
  • 40 van den Berg HM, Feldman BM, Fischer K, Blanchette V, Poonnoose P, Srivastava A. Assessments of outcome in haemophilia - what is the added value of QoL tools?. Haemophilia 2015; 21 (04) 430-435
    CrossrefPubMedGoogle Scholar
  • 41 Abshire T, Cox-Gill J, Kempton CL. , et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. J Thromb Haemost 2015; 13 (09) 1585-1589
    CrossrefPubMedGoogle Scholar
  • 42 Holm E, Abshire TC, Bowen J. , et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis 2015; 26 (04) 383-388
    CrossrefPubMedGoogle Scholar
  • 43 Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008; 34 (01) 128-141
    Article in Thieme ConnectPubMedGoogle Scholar